Hjem › Atopisk dermatitt (eksem) › Michigan
Kliniske studier for Atopisk dermatitt (eksem) i Michigan
14 studier for Atopisk dermatitt (eksem) søker deltakere på steder i Michigan.
Byer i Michigan
Offisiell studietekst (engelsk)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017, Ann Arbor
- Oakland Hills Dermatology- Site Number : 8400042, Auburn Hills
- Great Lakes Research Group - Bay City- Site Number : 8400052, Bay City
- og 3 flere
RekruttererObservasjonsstudie
Alder 12 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Troy
RekruttererFase 2
Alder 18 til 100 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Auburn Hills
- Enveda Investigative Site, Bay City
- Enveda Investigative Site, Clinton Township
- og 1 flere
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Detroit
- Investigational Site, Troy
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Derm Research Institute, PLC, Caledonia
RekruttererObservasjonsstudie
Alder 12 til 89 · Alle kjønn · Oppdatert 15. sep. 2026 · NCT07645820A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Revival Research Institute, LLC, Troy
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07223697FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Revival Research Institute, LLC, Troy
RekruttererFase 1Frivillige helsepersonell ønskes velkommen
Alder 18 til 70 · Alle kjønn · Oppdatert 22. jul. 2026 · NCT06564389A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Waterford
RekruttererFase 3
6 Months – 11 Years · Alle kjønn · Oppdatert 7. jul. 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Henry Ford Medical Center - New Center One /ID# 263522, Detroit
RekruttererFase 3
Alder 18 til 63 · Alle kjønn · Oppdatert 6. jul. 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Michigan Center for Research Company, Clarkston
- MI Skin Innovations, Northville
- Revival Research Institute LLC, Troy
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. mai 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7066, Auburn Hills
- Galderma Investigational Site 7071, Caledonia
- Galderma Investigational Site 7108, Grandville
- og 1 flere
RekruttererObservasjonsstudie
Alder 12 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT06988605Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- University of Michigan, Ann Arbor
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 10 til 55 · Alle kjønn · Oppdatert 25. nov. 2025 · NCT06300697Ethnic Differences in Mechanisms of Action of Dupilumab
- University of Michigan, Ann Arbor
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 6. nov. 2025 · NCT05268107A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 24. jan. 2025 · NCT06524635Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.